Sector
PharmaceuticalsOpen
₹841.5Prev. Close
₹847.35Turnover(Lac.)
₹968.2Day's High
₹854Day's Low
₹836.752 Week's High
₹97252 Week's Low
₹596Book Value
₹212.94Face Value
₹2Mkt Cap (₹ Cr.)
10,357.22P/E
22.03EPS
38.43Divi. Yield
2.66The sale will be conducted through the stock exchange mechanism, adhering to applicable legal requirements.
Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 24.51 | 24.51 | 1.96 | 1.96 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,113.7 | 2,029.81 | 750.79 | 399.73 |
Net Worth | 2,138.21 | 2,054.32 | 752.75 | 401.69 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 |
---|---|
Revenue | 1,885.16 |
yoy growth (%) | |
Raw materials | -905.49 |
As % of sales | 48.03 |
Employee costs | -149.13 |
Y/e 31 Mar( In .Cr) | Mar-2021 |
---|---|
Profit before tax | 470.94 |
Depreciation | -33.39 |
Tax paid | -119.36 |
Working capital | |
Other operating items |
Y/e 31 Mar | Mar-2021 |
---|---|
Growth matrix (%) | |
Revenue growth | |
Op profit growth | |
EBIT growth | |
Net profit growth |
Particulars (Rupees in Crores.) | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|
Gross Sales | 1,885.17 | 1,537.31 | 886.42 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 1,885.17 | 1,537.31 | 886.42 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 0.81 | 11.99 | 0.44 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Non Executive Dir.
Glenn Saldanha
Non Executive Director
V S Mani
Managing Director & CEO
Yasir Yusufali Rawjee
E D & Wholetime Director
Vinod Naik
Independent Non Exe. Director
Sridhar Gorthi
Independent Non Exe. Director
Manju Agarwal
Independent Non Exe. Director
Taruvai Laxminarayanan Easwar
Independent Non Exe. Director
Gita Nayyar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Glenmark Life Sciences Ltd
Summary
The company was incorporated as Zorg Laboratories Private Limited, a private limited company under the Companies Act, 1956 on 23 June 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune (RoC). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited pursuant to a special resolution passed by the shareholders of the Company on 25 July 2018 and a fresh certificate of incorporation dated 10 August 2018 was issued by the RoC. A shareholders resolution was passed on 13 August 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January 2019.The company is primarily engaged in the business of development,manufacture and marketing of Active Pharmaceutical Ingredients(APIs). The companys R&D facilities are located at Mahape,Ankleshwar and Dahej and manufacturing facilities are located at Ankleshwar,Dahej,Mohol and Kurkumbh.During the year 2018-19, the company allotted 4,50,090 Equity Shares of Rs. 10/- each on the conversion of loan given to Director. During the year, 15,00,000
Read More
The Glenmark Life Sciences Ltd shares price on N/A is Rs.₹844.85 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Life Sciences Ltd is ₹10351.71 Cr. as of 22 Jul ‘24
The PE and PB ratios of Glenmark Life Sciences Ltd is 22.03 and 4.45 as of 22 Jul ‘24
The 52-week high/low is the highest and lowest price at which a Glenmark Life Sciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Glenmark Life Sciences Ltd is ₹597.8 and ₹970 as of 22 Jul ‘24
Glenmark Life Sciences Ltd's CAGR for 5 Years at N/I%, 3 Years at 4.21%, 1 Year at 39.02%, 6 Month at 8.29%, 3 Month at 5.53% and 1 Month at 0.39%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.